Glenmark secures MHRA approval to launch Winlevi in the UK
Winlevi, licensed from Cosmo Pharmaceuticals, introduces a new topical approach to acne treatment
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Glenmark Pharmaceuticals
Glenmark launches Lacosamide Oral Solution, bioequivalent to Vimpat
Lacosamide Oral Solution, 10 mg/mL, enters the U.S. market with an annual market size of $57 million
Glenmark gets ANDA approval for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg
Glenmark’s Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), will be distributed in the US by Glenmark Therapeutics, US
Glenmark ranks No.1 in dermatologist prescriptions for protective emollients and derma therapy:…
Glenmark Pharmaceuticals has been ranked number 1 in dermatologists’ prescriptions in the protective emollients category and for…
Glenmark partners with Pfizer to launch Abrocitinib in India
When launched in India, it will be co-marketed under the brand names JABRYUS and CIBINQO by Glenmark and Pfizer respectively
Glenmark and Ichnos launch Ichnos Glenmark Innovation to accelerate new drug discovery in cancer…
The newly formed IGI features a pipeline of three innovative oncology molecules targeting multiple myeloma, acute myeloid leukemia…
Jiangsu Alphamab, 3D Medicines and Glenmark sign license pact for KN035 (Envafolimab)
Glenmark will be responsible for further developing, registering, and commercialising Envafolimab in India, Asia Pacific, Middle…
Glenmark launches biosimilar of anti-diabetic drug, Liraglutide, in India
It is priced at around Rs 100 for a standard dose of 1.2 mg (per day)
Glenmark gets USFDA nod for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, 10 mg
The tablets will be distributed in the US by Glenmark Pharmaceuticals US
Glenmark Pharma gets ANDA nod for Apremilast Tablets, 10 mg, 20 mg and 30 mg
Apremilast Tablets, 10 mg, 20 mg and 30 mg, is the generic version of Otezla Tablets, 10 mg, 20 mg and 30 mg, of Amgen